Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed lymphoproliferative disease * CD20-positive disease * Bidimensionally measurable disease OR abnormal cells detected in blood * Resistant or refractory to standard therapies and/or unlikely to benefit from additional standard therapies\* AND meets 1 of the following criteria: * Disease with anticipated response rate \< 20% after treatment with rituximab alone, including any of the following: * Diffuse large cell lymphoma * B-cell lymphoblastic lymphoma * Burkitt's lymphoma * Acute lymphocytic leukemia * Relapsed or progressive disease after prior treatment with rituximab, including any of the following: * Hodgkin's lymphoma * Hairy cell leukemia * Chronic lymphocytic leukemia/small lymphocytic lymphoma meeting any of the following criteria: * Received prior fludarabine phosphate-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies * Received prior anti-CD52 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy) * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment * B-cell prolymphocytic leukemia meeting any of the following criteria: * Received prior fludarabine phosphate- or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies * Received prior anti-CD52 monoclonal antibody therapy OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy) * Lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, or follicular lymphoma meeting any of the following criteria: * Received prior fludarabine phosphate- and/or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies * Received prior anti-CD20 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy * Received prior radioconjugated anti-CD20 monoclonal antibody therapy OR ineligible to receive such therapy * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment * Multiple myeloma meeting any of the following criteria: * Received prior alkylating agent-, thalidomide-, corticosteroid-, or bortezomib-containing regimens and relapsed after 1 year of treatment OR ineligible to receive such therapies due to comorbidities or allergies * Received prior high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy * Mantle cell lymphoma meeting the following criteria: * Received prior combination chemotherapy and anti-CD20 monoclonal antibody therapy and relapsed after treatment OR ineligible to receive such therapy * Diffuse large B-cell lymphoma meeting any of the following criteria: * Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy * Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR not a candidate to receive such therapy * Received prior radiolabeled anti-CD20 monoclonal antibody therapy for transformed large cell lymphoma OR ineligible to receive such therapy * Burkitt's lymphoma meeting any of the following criteria: * Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy * Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy * Lymphomatoid granulomatosis meeting any of the following criteria: * Received prior single-agent or combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment * Acute lymphocytic leukemia meeting any of the following criteria: * Received prior multi-agent combination chemotherapy administered in sequential induction, consolidation, and maintenance courses and relapsed during or after treatment OR ineligible to receive such therapy * Received prior chemotherapy with or without radiotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) and relapsed after treatment OR not a candidate for such therapy * Received prior treatment with chemotherapy with or without radiotherapy followed by allogeneic HSCT and relapsed after treatment (or not a candidate for such therapy) AND demonstrates persistent cytogenetic, fluorescent in situ hybridization, or molecular (reverse transcriptase-polymerase chain reaction) evidence of the bcr-abl fusion gene despite 6 weeks of treatment with imatinib mesylate NOTE: \*Not eligible to receive standard available salvage regimens anticipated to result in durable remission * No active CNS malignancy * Not considered a candidate for allogeneic HSCT * HLA-partially matched (≥ 2/6) related donor available PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Life expectancy \> 3 months * Not pregnant * Negative pregnancy test * Fertile women must use effective contraception * Bilirubin \< 1.5 times upper limit of normal (ULN) * AST \< 3.0 times ULN * Cardiac ejection fraction \> 35% * Absolute neutrophil count \> 1,000/mm³ (without cytokines) * Platelet count \> 50,000/mm³ (untransfused) * No significant organ dysfunction * No active uncontrolled infections * No hypersensitivity reaction to rituximab that has precluded completion of a 4-week course of rituximab therapy * No uncontrolled psychiatric illness or medical condition that would preclude tolerance of study treatment PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from prior therapy for at least 7 days * More than 30 days since prior cytotoxic chemotherapy * At least 14 days since prior steroids * At least 14 days since prior radiotherapy to non-target lesions